Introduction {#S0001}
============

Gastric cancer remains the second leading cause of cancer deaths worldwide.[@CIT0001] The treatment of gastric cancer patients depends on the exact assessment of gastric staging. The prognosis of patients with gastric cancer is also determined by the progress of the tumor, including lymph node metastasis and tumor invasion outside the stomach wall.[@CIT0002],[@CIT0003] More accurate staging methods are required to achieve the most effective treatment, thus leading to longer survival and better quality of life.

Preoperative understanding of clinical staging in gastric cancer is very useful in providing the best treatment for patients: for example, neoadjuvant (preoperative) chemotherapy can be used to treat AGC (i.e., tumors with lymph node metastases (N+)).[@CIT0004],[@CIT0005] In addition, early gastric cancer without lymph node metastasis (T1 tumors) (N0) can be resected through endoscopic without surgery.[@CIT0006],[@CIT0007] However, patients with gastric cancer with lymph node metastasis may have a lower survival rate and a higher risk of recurrence if they are treated through surgery alone. Thus, lymph node status is important in guiding treatment and predictive outcomes.

Several tools to diagnose lymph node metastasis of gastric cancer are available, such as multi-detector computed tomography (MDCT), positron emission tomography/computed tomography (PET/CT), magnetic resonance imaging (MRI), and endoscopic ultrasonography (EUS).[@CIT0008] MDCT is most widely used to assess lymph node staging of gastric cancer patients, mainly on the basis of lymph node size,[@CIT0009],[@CIT0010] but the limited sensitivity of MDCT results in false-negative findings.[@CIT0009],[@CIT0011] The overall accuracy and sensitivity of MDCT for N staging were about 63.8--64%, 43.3--55%.[@CIT0012],[@CIT0013] Diffusion-weighted imaging (DWI) and 18 F-Fluorodeoxyglucose PET/CT (18 F-FDG PET/CT) are relatively new imaging techniques used for preoperative staging of numerous cancers and both achieved a higher sensitivity and specificity than MDCT.[@CIT0014] Despite the continuous improvement of imaging technology, the accuracy of N staging of gastric cancer is still very low.[@CIT0015]

EUS in the staging of gastric cancer was first introduced in clinical practice in the 1980s, and it has been slow to accept as an important part of gastric cancer staging assessment. EUS can assess the depth of tumor invasion and whether the lymph nodes are involved. But its shortcomings include a high degree of reliance on the operator, the need for very professional technical skills, the inability to detect plane or fix lesions, and the inability to assess long-distance transfers.[@CIT0016],[@CIT0017]

EUS was useful in assessing gastric cancer T staging. Previous studies have found that the EUS diagnostic accuracy for T staging ranges from 43% to 88%.[@CIT0018]--[@CIT0022] However, the conclusions in studies on the accuracy of EUS in detecting lymph node metastasis of gastric cancer vary. Our study was conducted to review and perform a meta-analysis regarding the use of EUS in assessing the diagnostic accuracy of gastric cancer lymph node metastasis (N stage).

Materials And Methods {#S0002}
=====================

Study Selection Criteria {#S0002-S2001}
------------------------

Only gastric cancer cases confirmed by surgery preceded by EUS were included. For lymph node status (N stage), if there was no lymph node metastasis (N0) according to pathology, the patient was considered negative, whereas if one or more lymph nodes were metastatic (N+), the patient was considered positive. The EUS criteria used for the nodal invasion were lymph node morphology and size. Only studies containing a 2 × 2 table that could be extracted or calculated from for true-negative (TN), false-negative (FN), true-positive (TP), and false-positive (FP) results were included. All selected studies were previously published; thus, no ethical approval or patient consent was required.

Studies were excluded for the following reasons: i) the prognostic information for lymph node status was not reported in the studies; ii) the TN, FN, TP, and FP results could not be calculated considering the originally published data or could not get by email with corresponding author; and iii) especially, studies in which patients received neoadjuvant therapy were excluded because they might have biased the results through "downstaging" regression of lymph nodes.

Data Sources And Searches {#S0002-S2002}
-------------------------

A comprehensive electronic search of the MEDLINE, Web of Science, EMBASE, SpringerLink, and ScienceDirect databases was performed by two investigators to identify relevant articles published before April 2019 by two investigators. The search keywords used included: EUS, endoscopic ultrasound, ultrasound, gastric cancer, stomach neoplasm, tumor staging, staging, lymph nodes, metastasis, sensitivity, specificity, positive predictive value, and negative predictive value.

The species was defined as "human." We did not limit our search to publications from certain countries, but only articles published in English were identified. To retrieve additional publications, we manually searched reference lists from the included articles and relevant systematic and narrative reviews on the topic. We imported all citations identified in the databases above into a bibliographic database (EndNote, version X7, Thomson Reuters).

Data Extraction And Quality Assessment {#S0002-S2003}
--------------------------------------

To obtain 2 × 2 contingency tables from the included studies, TN, FN, TP, and FP results were extracted or calculated. The two authors independently searched and extracted the data. Any differences were resolved through mutual agreement.

Quality assessment of the included studies was performed by two independent reviewers using the recently developed version 2 of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool for diagnostic accuracy studies.[@CIT0023] Data extraction and quality assessment were performed by the same two researchers independently, and a consensus was reached when disagreements arose.

Data Synthesis And Analysis {#S0002-S2004}
---------------------------

Stata, version 12.0 (Stata Corp., College Station, TX, USA) with the "midas" and "metandi" commands was used.[@CIT0024] We performed meta-analysis with the bivariate random effects model to calculate the sensitivity and specificity of the combined diagnostic odds ratio (DOR) and EUS performance from diagnostic test data. In addition, hierarchical summary receiver operating characteristic (HSROC) curves based on the pooled data were computed for EUS performance and the area-under-the-curve (AUC) index for each technique. Then, we determined whether the differences in all indicators (sensitivity, specificity, and DOR) between different modalities were statistically significant by using the *Z* test. All p values presented are two-sided, and the results were considered significant only if the p value was less than or equal to 0.05.

A "shoulder-arm" shape in the ROC plane can suggest a threshold effect. The Q statistic of the chi-square test and the inconsistency index (I^2^) were used to estimate the heterogeneity between included studies, and p \<0.1 or I^2^ \>50% indicated heterogeneity.[@CIT0025]

We expected to find between-study variation in the analysis results, as is common in diagnostic accuracy studies. Subgroup analysis was used to assess the effects of various factors on the diagnostic accuracy of EUS and to investigate the potential sources of heterogeneity; we additionally performed meta-regression with the bivariate model including covariates (publication year, country, study sample size, type of EUS array, and stomach site).

Publication bias was assessed through an asymmetry test and Deeks' funnel plot in Stata.[@CIT0026] An inverted symmetrical funnel plot with p \>0.05 was considered to indicate the absence of publication bias.

Results {#S0003}
=======

We identified 2328 reference articles by using the search criteria. Among these, the two authors independently selected and reviewed 376 relevant full-text articles. Finally, 50 studies (*n*=5223), which were published as full-text articles in peer-reviewed journals, were included in the meta-analysis.[@CIT0021],[@CIT0027]--[@CIT0075] The details of the included studies are shown in [Figure 1](#F0001){ref-type="fig"}, the PRISMA checklist and [Table 1](#T0001){ref-type="table"}.Table 1Main Features Of The 50 Eligible Studies (*N*=5223) Included StudiesIDSample SizeCountryConformatory TestEquipmentFrequency (MHz)Stomach SiteTio et al, 1986[@CIT0027]11NetherlandsSurgeryRadialUnreportedAnyMurata et al, 1988[@CIT0028]146JapanSurgeryRadial7.5--10AnyTio et al, 1989[@CIT0029]80NetherlandsSurgeryRadial7.5--12AnyBotet et al, 1991[@CIT0030]50United statesSurgeryRadial7.5--12AnyCerizzi et al, 1991[@CIT0031]21ItalySurgeryRadial7.5--12AnyCaletti et al, 1993[@CIT0032]35ItalySurgeryRadial7.5--12AnyDittler et al, 1993[@CIT0033]254GermanySurgeryRadial7.5--12AnyGrimm et al, 1993[@CIT0034]147GermanySurgeryRadial7.5AnyZiegler et al, 1993[@CIT0035]108GermanySurgeryRadial7.5--20AnyFrancois et al, 1996[@CIT0036]29FranceSurgeryRadial7.5--12CardiaMassari et al,1996[@CIT0037]65ItalySurgeryRadial7.5--12AnyPerng et al, 1996[@CIT0038]76TaiwanSurgeryRadial7.5--12AnyHamada et al, 1997[@CIT0039]149JapanSurgeryRadial7.5--20AnyAkahoshi et al, 1998[@CIT0040]73JapanSurgeryRadial15AnyHunerbein et al, 1998[@CIT0041]22GermanySurgeryRadial12.5AnyWang et al, 1998[@CIT0042]119TaiwanSurgeryRadial7.5--12AnyDe Manzoni et al, 1999[@CIT0043]29ItalySurgeryRadial7.5CardiaNakamura et al, 1999[@CIT0044]31JapanSurgeryNRNRAnyMancino et al, 2000[@CIT0045]79ItalySurgeryRadial7.5--12AnyTseng et al, 2000[@CIT0046]74TaiwanSurgeryRadial7.5--12AnyWillis et al, 2000[@CIT0047]116GermanySurgeryRadial7.5--12AnyChen et al, 2002[@CIT0048]57TaiwanSurgeryRadial7.5--20AnyXi et al, 2003[@CIT0049]32ChinaSurgeryRadial7.5--20AnyBhandari et al, 2004[@CIT0050]48KoreaEMR or SurgeryRadial20AnyHabermann et al, 2004[@CIT0051]51GermanySurgeryRadial7.5--12AnyJavaid et al, 2004[@CIT0052]112IndiaSurgeryRadial7.5AnyPolkowski et al, 2004[@CIT0053]88PolandSurgeryRadial7.5--12AnyShimoyama et al, 2004[@CIT0054]45JapanSurgeryLinear7.5CardiaLee et al, 2005[@CIT0055]241ChinaSurgeryLinear7.5, 12AnyPedrazzani et al, 2005[@CIT0056]51ItalySurgeryLinear7.5CardiaAng et al, 2006[@CIT0057]57SingaporeSurgeryRadial7.5--12AnyArocena et al, 2006[@CIT0058]17SpainSurgeryLinear12.5AnyGanpathi et al, 2006[@CIT0059]102SingaporeSurgeryRadial7.5--12AnyPotrc et al, 2006[@CIT0060]82SloveniaSurgeryRadial7.5--12AnyTsendsuren et al, 2006[@CIT0061]41ChinaSurgeryLinear5--7.5AnyBarbour et al, 2007[@CIT0062]206USASurgeryRadial7.5--12CardiaBentrem et al, 2007[@CIT0063]218United StatesSurgeryNR7.5--12AnyTan et al, 2007[@CIT0064]63ChinaSurgeryRadial7.5--20AnyBlackshaw et al, 2008[@CIT0065]44UKSurgeryRadial7.5--12CardiaLok et al, 2008[@CIT0066]75Hong KongSurgeryRadial12--20AnyPark et al, 2008[@CIT0067]40KoreaSurgeryRadial7.5---12AnyAhn et al, 2009[@CIT0068]71KoreaSurgeryRadial5--12AnyHwang et al, 2010[@CIT0021]277KoreaSurgeryRadial5--20AnyRepiso et al, 2010[@CIT0069]36SpainSurgeryRadial7.5--20AnyBohle et al, 2011[@CIT0070]62GermanySurgeryRadial20AnyZheng 2011[@CIT0071]165ChinaSurgeryRadial7.5--12AnyKutup et al, 2012[@CIT0072]123GermanySurgeryRadial7.5--12AnySpolverato et al, 2015[@CIT0073]149USASurgeryRadial7.5--12AnyGiganti et al, 2016[@CIT0074]52ItalySurgeryRadial5--10AnySerrano et al, 2016[@CIT0075]69USASurgeryRadial7.5,10Any Figure 1Flowchart illustrating the selection of studies.

[Figure 2](#F0002){ref-type="fig"} shows that QUADAS2 criteria were used to assess the quality of the eligible studies; the values ranged from 20% to 100% high-quality studies in the four domains of the bias part and three domains of the applicability part. For most QUADAS2 domains (3/4), all studies were classified as high quality.Figure 2Graphical display for QUADAS-2 results regarding the proportion of studies with low, high, or unclear risk of bias.

Lymph Node Status (N-Stage) {#S0003-S2001}
---------------------------

The combined values of sensitivity, specificity, likelihood ratio, and DOR, as well as the values for the single studies, are displayed in [Figure 3](#F0003){ref-type="fig"}. [Figure 4](#F0004){ref-type="fig"} shows the HSROC curve including the summary point and its 95% confidence and prediction intervals.Figure 3EUS diagnostic performance to distinguish lymph node-positive from lymph node-negative tumors: forest plot of the studies included in the meta-analysis.Figure 4Hierarchic summary receiver operating characteristic (ROC) (solid line) plot with summary point with 95% CI area (circled area).

The summary sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and DOR were 0.82 (95% CI 0.78 to 0.85), 0.68 (95% CI 0.63 to 0.73), 2.6 (95% CI 2.2 to 3.0), 0.27 (95% CI 0.22 to 0.32), and 10 (95% CI 8 to 12), respectively, and the HSROC area AUROC was 0.83 (0.79--0.86). The summary sensitivity (but not specificity) was relatively high, but the forest plot showed that the between-study heterogeneity was substantial ([Figure 3](#F0003){ref-type="fig"}). The Fagan plot ([Figure 5](#F0005){ref-type="fig"}) indicated that the previous probability of being classified as N+ increased from 50% (average prevalence of N+ cases) to 70% when positive, and decreased to 20% when negative, when EUS was used, thus indicating that EUS may be clinically informative.Figure 5EUS diagnostic performance to distinguish lymph node-positive from lymph node-negative tumors: Fagan plot (Bayesian nomogram).

The between-study heterogeneity was significant both for sensitivity (I^2^: 79.35%, Q test P=0.001) and for specificity (I^2^: 91.4%, Q test P=0.001). The proportion of heterogeneity was substantial (47%), probably because of the threshold effect. Subgroup and sensitivity analyses ([Table 2](#T0002){ref-type="table"}) showed that the publication year was related to the heterogeneity. No evidence of notable publication bias was found according to Deeks' funnel plot asymmetry test.Table 2Subgroup And Sensitivity Analysis For N0 Versus N+ Gastric TumorsVariableCategoryStudiesSensitivity (95% CI)Specificity (95% CI)P ValueSample size\>100140.82 \[0.76--0.88\]0.70 \[0.61--0.78\]0.96\<100360.82 \[0.77--0.87\]0.68 \[0.62--0.75\]Year of publication2000 or later320.81 \[0.76--0.86\]0.66 \[0.60--0.72\]0.02Before 2000180.85 \[0.79--0.91\]0.74 \[0.67--0.82\]CountryWestern280.79 \[0.73--0.85\]0.73 \[0.67--0.79\]0.12Eastern220.85 \[0.81--0.90\]0.64 \[0.56--0.71\]EUS arrayRadial440.82 \[0.78--0.86\]0.70 \[0.64--0.75\]0.67Linear60.84 \[0.74--0.94\]0.62 \[0.46--0.78\]Tumor siteCardia region60.83 \[0.71--0.94\]0.76 \[0.63--0.88\]0.46Any site440.82 \[0.78--0.86\]0.68 \[0.62--0.73\]

Discussion {#S0004}
==========

This system evaluated data from many lines of research including large series of patients (*n*=5223) to assess the diagnostic performance of EUS in gastric cancer N staging. Using the statistical methods of diagnostic meta-analysis, we quantified the existing evidence and found that EUS might be clinically informative for gastric cancer N staging overall. This study may provide clinically useful information for physicians for making clinical decisions.

This meta-analysis indicated that the sensitivity of EUS for gastric cancer N staging was relatively high (82%). However, the specificity of EUS in the diagnosis of N staging in gastric cancer was not high (68%). Moreover, the EUS also had a relatively high PLR (2.6) and a relatively low NLR (0.27), thus indicating that EUS performs well in identifying the true lymph node status (positive) and in excluding false lymph node status (negative). In addition, EUS had a relatively high DOR (10) in the diagnosis of N staging of gastric cancer, thus indicating that EUS performs better at diagnosing than excluding N staging in gastric cancer. The heterogeneity between different studies was determined with HSROC curves. The HSROC curves for EUS showed that the value for the area under the curve was very close to 1 (0.83), thus indicating that EUS is a good diagnostic test for N staging in gastric cancers.

Our findings support the potential value of EUS in N staging in gastric cancer. Although this method is not the first choice, it is considered clinically useful to guide doctors in disease staging and then choosing the most appropriate individual treatment strategy according to personalized medicine principles. However, physicians must note that EUS has relatively low specificity in diagnosing lymph node status (positive versus negative).

EUS has unparalleled advantages over other alternative options: it does not require general anesthesia or hospitalization, and the inspection process is safe and minimally invasive, with a low incidence of complications.[@CIT0076]--[@CIT0079]

We observed considerable heterogeneity among the study results, and we performed subgroup analysis and meta-regression. The EUS criteria for nodal metastasis and the technology of EUS have improved over the past two decades. This improvement has affected the staging of gastric cancer and has contributed to most of the heterogeneity. However, this change did not greatly improve N staging, and although the pooled specificity of EUS is high, the sensitivity is not as high. Publication bias did not significantly affect the summary estimates, as shown in funnel plots in this meta-analysis.

MDCT is most widely used to assess lymph node staging in gastric cancer patients, mainly on the basis of lymph node size, thus potentially leading to insufficient staging when the most recent edition (7th, 2010) of the AJCC TNM classification is used.[@CIT0080] When N stages are determined through MRI examination, there are effects of factors such as long examination times, gastrointestinal peristalsis, and multiple breath-holding times. PET examination is insensitive to metastatic lymph nodes \<5 mm, owing to gastric physiological uptake and creep, limitations of the inherent resolution, and primary tumor uptake coverage.

The advantage of EUS is its ability to differentiate the layers of the gastric mucosa. Notably, the accuracy of EUS in staging gastric cancers varies, and EUS has been reported to understage the depth of invasion and overstage nodal invasion because of inflammation in the lymph nodes and extension greater than 20 mm,[@CIT0081] which physicians should mind.

There are several strengths of this review, primarily the number of patients enrolled (*n*=5223). A large number of patients enrolled ensures good representation of the results and improves statistical performance. Moreover, we provided relatively comprehensive meta-analysis indexes to add further information regarding clinical use, from summary diagnostic performance to Bayesian analysis including Fagan plots and likelihood ratio matrices. There are several limitations of this study, primarily the markedly high heterogeneity, which may have limited the reliability and reproducibility. Furthermore, the data available in the literature did the challenges for the identification of possible heterogeneity. Further network meta-analyses may address some of the problems described above.
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